m+Medelevator.RU
← Поиск публикаций
Endoscopy international open · 2026

Completion Small Bowel Capsule Endoscopy after Device-assisted Enteroscopy in Management of Patients with Small Bowel Disease.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Sihag Sandeep, Leung Edric, Costigan Conor, McNamara Deirdre

Аннотация

Background and study aims Diagnostic yields of small bowel capsule endoscopy (SBCE) and device-assisted enteroscopy (DAE) are known to be similar. SBCE is normally recommended as the initial diagnostic test, with DAE reserved for therapeutic indications. As most DAE procedures are not pan-enteric, a completion capsule may be of benefit to identify residual or overlooked disease. Our aim was to assess the clinical utility of completion SBCE performed following DAE. Patients and methods A retrospective analysis of completion capsules post double balloon enteroscopy (DBE) from a single referral center was performed. Cases were identified by cross-referencing endoscopy and capsule databases. A completion capsule was defined as a capsule endoscopy requested on the enteroscopy report and performed after DAE without a new clinical indication. Main outcome measures included diagnostic yield of completion SBCE and impact on management. Results Of 350 DBE patients, 70 (21%) underwent a completion SBCE, 27 of the 70 (39%) on the same day as DBE. In all, 39 of the 70 (56%) had undergone SBCE before DBE. Both completion rate (91%; 64/70) and diagnostic yield (43%; 30/70) surpassed the European Society of Gastrointestinal Endoscopy standards. A positive completion capsule resulted in a change in management in 80% of patients (24/30). Conclusions Completion SBCE is feasible and effective, detecting and localizing clinically significant disease in over one-third of cases, while also reducing the need for further investigations in those with negative studies.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты